Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Younes, Anas; Brody, Joshua; Carpio, Cecilia; Lopez-Guillermo, Armando; Ben-Yehuda, Dina; Ferhanoglu, Burhan; Nagler, Arnon; ÖZCAN, MUHİT; Avivi, Irit; Bosch, Francesc; Caballero Barrigon, Maria; Hellmann, Andrzej; Kuss, Bryone; Ma, David; DEMİRKAN, FATİH; Yagci, ABDULLAH; Horowitz, Netanel; Marlton, Paula; Cordoba, Raul; Wrobel, Tomasz; Buglio, Daniela; Streit, Michael; Hodkinson, Brendan; Schaffer, Michael; Alvarez, John; Ceulemans, Rob; Balasubramanian, Sriram; de Jong, Jan; Wang, Shean-Sheng; Fourneau, Nele; Jurczak, Wojciech

doi:10.1016/s2352-3026(18)30217-5

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Atıf İçin Kopyala

Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu B., ...Daha Fazla

LANCET HAEMATOLOGY, cilt.6, sa.2, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 6 Sayı: 2
Basım Tarihi: 2019
Doi Numarası: 10.1016/s2352-3026(18)30217-5
Dergi Adı: LANCET HAEMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Gazi Üniversitesi Adresli: Evet

Özet

Background Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases.